FDA Approves First Ever Rapid-Acting Treatment for Major Depressive Disorder


Dextromethorphan HBr-bupropion HCI (Auvelity) is developed by Axsome Therapeutics.

FDA Approved First Ever Rapid-Acting Treatment for Major Depressive Disorder

The US Food and Drug Administration (FDA) has approved dextromethorphan HBr-bupropion HCI (Auvelity) for the treatment of adult patients with major depressive disorder (MDD).

The treatment, developed by Axsome Therapeutics, represents the first and only rapid-acting oral medicine approved by the FDA for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo beginning at 1 week.

The approval is based on clinical trials where the rapid antidepressant effects of the treatment were sustained at all subsequent timepoints. The trials involved more than 1100 patients with depression, including the GEMINI placebo-controlled study and the ASCEND study comparing Auvelity to bupropion sustained-release tablets.

In the GEMINI study, the treatment was statistically significantly superior to placebo in the improvement of depressive symptoms, measured by the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.

In the ASCEND study, the treatment was statistically significant to bupropion sustained-release tablets 105 mg twice daily.

“The approval of Auvelity represents a milestone in depression treatment based on its novel oral NMDA antagonist mechanism, its rapid antidepressant efficacy demonstrated in controlled trials, and a relatively favorable safety profile,” Maurizio Fava, MD, Psychiatrist-In-Chief, Department of Psychiatry, Massachusetts General Hospital, Executive Director, Clinical Trials Network & Institute, Associate Dean for Clinical & Translational Research, and Slater Family Professor of Psychiatry, Harvard Medical School said in a statement. “Given the debilitating nature of depression, the efficacy of Auvelity observed at one week and sustained thereafter may have a significant impact on the current treatment paradigm for this condition.”

Related Videos
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
Awaiting FDA Decision on MDMA Assisted Therapy, with Bessel van der Kolk, MD
Bessel van der Kolk, MD: The Future of MDMA Assisted Therapy in PTSD
Bessel van der Kolk, MD: What MDMA-Assisted Therapy Taught us About PTSD
Why Are Adult ADHD Cases Climbing?
Depression Screening: Challenges and Solutions at the Primary Care Level
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.